ensuring knowledge, enhancing quality
A 'not-for-profit' organisation,
run for pharmaceutical analysts by pharmaceutical analysts


Thursday 28th June 2018
Harmonisation and application of BCS-based Guidance
Royal Society of Chemistry, London
Purpose of the Meeting
This symposium will look at the progress of the ICH M9 guidance (Biopharmaceutics Classification System (BCS)-Based Biowaivers) from a regulatory and industrial perspective; evaluating barriers to implementation from a solubility, permeability and dissolution perspective. Attendees will also better understand the progress that has been achieved by the International Pharmaceutical Federation (FIP) initiative on biowaiver monographs for essential drugs. These monographs are in-depth literature reviews, assessing whether a biowaiver can be recommended for a new formulation of an active pharmaceutical ingredient (API) based on publicly available data. It is also the intention of the meeting to seek feedback from JPAG members via a panel discussion, which in turn can be fed back to the ICH M9 Expert Working Group as part of the public consultation process. In addition, the symposium will look to update delegates on progress in the related fields of clinically relevant dissolution specifications and outcomes from the IMI OrBiTo consortium.

Proposed outcomes
• Awareness of current requirements and future developments and challenges
• Opportunities to challenge / raise concerns and understand from experts in this field as to how they might be addressed
• Opportunities to provide their feedback into the ICH M9 process via an interactive panel discussion
• Hear from experts what is actually happening in practice and what the future state will look like.

Who should attend
This symposium should be attended by those involved in in vitro dissolution testing in R&D and production, in the compilation of regulatory dossiers and in the planning and execution of biowaivers in lieu of bioequivalence studies- particularly those working in consumer healthcare and developing markets. This symposium will also appeal to those working in CMOs and quality management.

Dr Andreas Abend - Merck
Dr Bertil Abrahamsson - AstraZeneca
Dr James Butler - GlaxoSmithKline
Dr David Elder - JPAG/Consultant
Dr Nikoletta Fotaki - University of Bath
Dr James Mann - AstraZeneca
Dr Mark McAllister - Pfizer
Dr Henrike Potthast - BfARM



You will have access to materials for meetings that you have attended.

You will need to Sign In to activate access to your additional options.
Once Signed in, click on RESOURCES and look under MY PAST MEETINGS.

Symposium - October 2011

Delegates at a symposium held at the Royal Pharmaceutical Society

© Joint Pharmaceutical Analysis Group 2018
Website by Delta Consultancy Services